Participants will receive a single injection of the imaging agent, followed by a series of imaging sessions that combine PET and CT scans to look at the transplanted kidney, nearby lymph nodes, spleen, liver and bone marrow. A small blood sample will also be taken to measure immune cells using a laboratory technique called flow cytometry. The study lasts for a short period of time after the injection, during which the imaging and blood tests are performed to assess the distribution of the agent and the activity of immune cells.

Adults who have had a kidney transplant are assigned to one of the study treatments. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known to the doctors and the participants. Frexalimab is given as an injection, while tacrolimus is taken by mouth as a capsule. The study follows participants for several years after transplantation to observe how the kidney is doing and to watch for signs of rejection, graft loss, death, and side effects.

During the study, regular checkups are done to monitor kidney function, general health, and possible unwanted effects of treatment. The study also looks at new health problems that can happen after a transplant, such as high blood pressure, abnormal blood fats, and diabetes. eGFR is one of the kidney tests used in the study; it is an estimate of how well the kidney is filtering the blood.

The treatment involves the administration of MSC through an intravenous infusion, which is a process where the cell suspension is delivered directly into a vein. During the study, the focus is on monitoring how the body responds to these cells and observing any changes in kidney function or immune activity. Participants will be monitored to ensure the procedure is safe and to see if the treatment helps prevent further damage to the transplanted kidney.

Participants in this study will receive tegoprubart through an intravenous (IV) infusion, which means it will be given directly into a vein. The study will monitor participants over a long period to check for any side effects and to see how well the kidney is functioning. The study will also compare the results with those of other treatments to ensure the best possible outcomes for kidney transplant recipients.

Throughout the study, researchers will keep track of any health changes, including side effects and how well the kidney is working. This will help determine the safety and effectiveness of tegoprubart in the long term. The study aims to provide valuable information that could improve the care and treatment of people who have received a kidney transplant.

The purpose of the study is to determine the effectiveness and safety of imlifidase in enabling kidney transplants for these patients. Participants will receive the treatment through an intravenous infusion, which means the medication is delivered directly into the bloodstream. The study will follow patients for one year after their transplant to monitor their health and the success of the transplant.

Throughout the study, researchers will assess various health indicators, such as kidney function and patient survival, to understand the impact of imlifidase. The study will also compare results with other groups of patients who have received kidney transplants without this treatment. This research aims to provide valuable insights into improving transplant outcomes for patients with high antibody levels.

The purpose of the study is to determine if adding tocilizumab to standard care treatment works better than standard care alone in preserving kidney function in transplant recipients who have this type of rejection. The medication will be given as a 162 mg injection under the skin for a period of 24 months.

During the study, participants will have their kidney function monitored through blood tests that measure how well their kidneys are filtering waste products from their blood. They will also have kidney tissue samples taken and undergo other medical tests to check their overall health and the condition of their transplanted kidney. The total duration of monitoring will last for 36 months, with regular check-ups to assess the kidney’s function and the participant’s general health.

The purpose of the study is to assess how well the transplanted kidney functions 12 months after the transplant in patients treated with Tegoprubart compared to those treated with Tacrolimus. Participants in the study will receive either Tegoprubart or Tacrolimus, along with other standard medications used in kidney transplantation, such as Mycophenolate Mofetil and Prednisolone. The study will also include a placebo group to help understand the effects of the treatments being tested. The study will last for up to 12 months, during which participants will have regular check-ups to monitor their kidney function and overall health.

Throughout the study, participants will be closely monitored to ensure their safety and to gather information on how well the treatments are working. The main focus will be on measuring the kidney’s ability to filter waste from the blood, known as the estimated glomerular filtration rate (eGFR). Other aspects, such as the rate of kidney function decline and the overall survival of both the patient and the transplanted kidney, will also be evaluated. This study is an important step in finding new and potentially more effective treatments for patients undergoing kidney transplantation.

During the study, children will receive imlifidase through an intravenous infusion, which means the medicine is given directly into a vein. The study will also involve other medications like methylprednisolone, a type of corticosteroid that helps reduce inflammation, and rituximab, which is used to lower certain immune responses. The trial will monitor the children’s health and kidney function for up to five years after the transplant to ensure the treatment is safe and effective. This includes checking how well the new kidney is working and looking for any side effects or complications.

The study will also use a placebo, which is a substance with no active medication, to compare the effects of the treatment. The trial aims to provide valuable information on how well imlifidase works in helping children receive a kidney transplant and improve their quality of life. By participating in this study, researchers hope to find a way to make kidney transplants possible for children who are highly sensitive and have limited options for donors.

The purpose of the study is to observe the long-term outcomes of patients who received imlifidase before their kidney transplant. The study will follow these patients over several years to see how well their transplanted kidneys function and to monitor their overall health. This includes checking for any signs of the body rejecting the new kidney, which is known as graft failure, and assessing kidney function through tests like the estimated Glomerular Filtration Rate (eGFR), which measures how well the kidneys are filtering waste from the blood.

Participants in the study will be monitored for up to five years after their transplant. The study will also look at patient survival rates, the health of the transplanted kidney, and any side effects related to the imlifidase treatment. Additionally, the study will evaluate the patients’ ability to participate in social activities and their overall quality of life. This information will help doctors understand the long-term benefits and risks of using imlifidase in kidney transplant patients.